Currently, the analyst consensus on Sino Biopharmaceutical is a Strong Buy with an average price target of HK$8.47, implying a 64.46% upside from current levels. In a report released on July 13, Morgan Stanley also maintained a Buy rating on the stock with a HK$7.80 price target.
SBMFF market cap is currently HK$91.71B and has a P/E ratio of 34.14.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBMFF in relation to earlier this year.
